How it works:
Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue. It enhances insulin secretion when glucose is high, reduces glucagon secretion, and slows gastric emptying, supporting glycaemic control and weight loss.
Recommended for:
Studies and trials:
Clinical studies (LEAD Programme, SCALE Obesity and Prediabetes) demonstrated liraglutide’s efficacy in reducing HbA1c, lowering weight, and decreasing cardiovascular risks.
The drug is injected subcutaneously once daily, preferably at the same time of day. The dosage is adjusted individually by a physician according to glucose level and tolerance.
Adverse effects: